

DIABETIC FOOT WOUND  
BIBLIOGRAPHY  
Provided to Medicare/Medicaid  
for Coverage of HBOT Treatment of Diabetic Foot Wounds  
by Paul G. Harch MD

1. Gottlieb SF. Oxygen under pressure and microorganisms. In: *Hyperbaric Oxygen Therapy*. Davis JC, Hunt TK, eds. Undersea Medical Society, Inc., Bethesda, MD, 1986. p.79.
2. Hyperbaric Oxygen Therapy Committee Report, 1999. Hampson NB, Chairman and Ed. Undersea and Hyperbaric Medical Society. Kensington, Maryland, 1999. p. 1.
3. Hyperbaric Oxygen Therapy, Its Use and Appropriateness. Office of Inspector General, Department of Health and Human Services. June Gibbs Brown, Inspector General. October 2000. OEI 06-99-00090.
4. Harch PG and Neubauer RA. Hyperbaric Oxygen Therapy in Global Ischemia, Anoxia, and Coma. Chapter 18, Textbook of Hyperbaric Medicine, 3<sup>rd</sup> Edition. Jain KK, ed. Hogrefe and Huber Publishers, Gottingen, Germany, 1999.
5. Sapico FL, Witte JL, Canawati HN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. *Rev Inf Dis*, 1986; 6(Suppl 1): S171-177.
6. Millington JT and Norris TW. Effective treatment strategies for diabetic foot wounds. *J Fam Pract*, November 2000; 49(11, suppl):S40-48.
7. Kertesz D, Chow AW. Infected pressure and diabetic ulcers. *Infect Dis* 1992; 8:835-53.
8. Edmonds ME, Blundell MP, Morris ME, Cotton LT, Watkins PI. Improved survival of the diabetic foot: the role of the specialised foot clinic. *Q J Medicine* 1986; 60: 763-771.
9. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. *Diabetes Care* 1990; 13:513-21.
10. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer: the Seattle Diabetic Foot Study. *Diabetes Care* 1999; 22: 1036-42.
11. Boulton AJ, Kubrusly DB, Bowker JH, et al. Impaired vibratory perception and diabetic foot ulceration. *Diabetic Med* 1986; 3: 335-37.
12. McNeely MJ, Boyko EJ, Ahroni JH, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration: how great are the risks? *Diabetes Care* 1995; 18:216-19.
13. Lavery LA, Armstrong DG, Vela SA, Quebedeaux TL, Fleischli JG. Practical criteria for screening patients at high risk for diabetic foot ulceration. *Arch Intern Med* 1998; 158: 157-62.
14. Lavery L, Gazewood JD. Assessing the feet of patients with diabetes. *J Fam Pract* 2000; 49(11): S9-16.
15. Mueller MJ, Minor SD, Diamond JE, Blair VP. Relationship of foot deformity to ulcer location in patients with diabetes mellitus. *Phys Ther* 1990; 70: 356-62.
16. Molenaar DM, Palumbo PJ, Wilson WR, et al. Leukocyte chemotaxis in diabetic patients and their nondiabetic first degree relations. *Diabetes* 1976; 25: 880-887.
17. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. *Am J Surg* 1998; 176(Suppl 2A): 5S-10S.
18. Foster DW. Diabetes Mellitus, Chapter 319. In: *Harrison's Principles of Internal Medicine, 12<sup>th</sup> Ed*. Wilson, Braunwald, Isselbacher, Petersdorf, Martin, Fauci, Root, eds. McGraw-Hill, Inc, NY, NY, 1999. p.1739-59.
19. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol* 1996; 27: 567-74.
20. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease and foot ulceration. *Diabetes* 1998; 47: 457-63.
21. Schaffer MR, Tantry U, van Wesep RA, Barbul A. Nitric oxide metabolism in wounds. *J Surg Res* 1997; 71:25-31.
22. Sheffield PJ. Tissue oxygen measurements with respect to soft-tissue wound healing with normobaric and hyperbaric oxygen. *Hyperbaric Oxygen Review* 1985; 6(1): 18-46.
23. Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower extremity ulcers. *Diabetes* 1991; 40: 1305-1313.
24. Reiber GE, Pecoraro RE, Keopesell TD. Risk factors for amputation in patients with diabetes mellitus. *Ann Int Med* 1992; 117: 97-105.
25. Pecoraro RE. The nonhealing diabetic ulcer—A major cause for limb loss. *Prog Clin Biol Res* 1991; 365: 27-43.
26. Boykin JV. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management. *Adv Skin Wound Care* 2000; 13: 169-74.

DIABETIC FOOT WOUND  
BIBLIOGRAPHY  
Provided to Medicare/Medicaid  
for Coverage of HBOT Treatment of Diabetic Foot Wounds  
by Paul G. Harch MD

27. Van Meter K. Systemic hyperbaric oxygen therapy as an aid in resolution of selected chronic problem wounds. In: *Chronic Wound Care, Second Edition*. Krasner D, Kane D, eds. Wayne, PA, Health Management Publications, Inc., 1997, p 260-275.
28. Knighton D, Hunt TK, Schouenstuh H, et al. Oxygen tension regulates the expression of angiogenesis factor by macrophages. *Science* 1983; 221: 1283-1285.
29. Davis JC, Buckley CJ, Barr PO. Compromised soft tissue wounds: correction of wound hypoxia. In: *Problem Wounds: The Role of Oxygen*. Davis JC, Hunt TK, eds. Elsevier, NY, 1988, p. 143-4.
30. Hohn DC, MacKay RD, Halliday B, Hunt TK. Effect of O<sub>2</sub> tension on microbicidal functions of leukocytes in wounds and in vitro. *Surg Forum* 1976; 27: 18-20.
31. Travis J, Salvesen GS. Human plasma proteinase inhibitors. *Ann Rev Biochem* 1985; 52: 655-709.
32. Lawrence DA, Loskutoff DJ. Inactivation of plasminogen activator inhibitor by oxidants. *Biochemistry* 1986; 25: 6351-5.
33. Silver IA. Local systemic factors which affect the proliferation of fibroblasts. In: *Biology of the Fibroblasts*. Kulomen E, ed. Academic Press, New York 1973, p. 507-520.
34. Siddiqui A, Galiano RD, Connors D, et al. Differential effects of oxygen on human dermal fibroblasts: acute versus chronic hypoxia. *Wound Rep Reg* 1966; 4: 211-218.
35. Niinikoski J. The effect of oxygen supply on wound healing and formation of experimental granulation tissue. *Acta Physiol Scand* 1969; 334: 1-72.
36. Niinikoski J, Henghan C, Hunt TK. Oxygen tensions in human wounds. *J Surg Res* 1972; 12: 77.
37. Hunt TK, Twomey P, Zederfeldt B, et al. Respiratory gas tension and pH in healing wounds. *Am J Surg* 1967; 114: 302-308.
38. Hunt TK, Linsey M, Grislis G, et al. The effect of differing ambient oxygen tensions on wound infection. *Ann Surg* 1975; 181: 35-39.
39. Hunt TK. Disorders of repair and their management. In: *Fundamentals of Wound Management*. Hunt TK, Dunphy JE, eds. Appleton-Century-Crofts, New York, 1979, p.68-168.
40. Hunt TK, Pai MP. The effect of varying ambient oxygen tensions on wound metabolism and collagen synthesis. *Surg Gynecol Obstet* 1972; 135: 561-567.
41. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA. The biosynthesis of collagen and its disorders. *N Engl J Med* 1979; 301: 13-23, 77-85.
42. La Van FB, Hunt TK. Oxygen and wound healing. *Clinic Plast Surg* 1990; 17(3): 463-472.
43. Mader JT, Gukian JC, McGoss DL, Reiniarz JA. Therapy with hyperbaric oxygen for experimental osteomyelitis due to staph aureus in rabbits. *J Infectious Diseases* 1978; 138: 312-318.
44. Kivissari J, Niinikoski J. Effects of hyperbaric oxygenation and prolonged hypoxia on healing of open wounds. *Acta Chir Scand* 1976; 141: 14-19.
45. Mason J, O'Kaeffet C, Hutchinson A, et al. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II: treatment. *Diabet Med* 1999; 16: 889-909.
46. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system: the contribution of depth, infection, and ischemia to risk of amputation. *Diabetes Care* 1998; 21: 855-59.
47. Adler AI, Boyko EJ, Ahroni JH, Smith DG. Lower-extremity amputation in diabetes: the independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. *Diabetes Care* 1999; 22: 1029-35.
48. Knighton DR, Fiegel VD. Oxygen as an antibiotic: the effect of inspired oxygen on infection. *Arch Surg* 1990; 125: 97-100.
49. Chang N, Mathes SJ. Comparison of the effect of bacterial inoculation in musculocutaneous and random-pattern flaps. *Plast Reconstr Surg* 1982; 70: 1-10.
50. Gottrup F, Firmin R, Hunt TK, Mathes SJ. The dynamic properties of tissue oxygen in healing flaps. *Surgery* 1984; 95: 527-536.
51. Knighton DR, Halliday B, Hunt TK. Oxygen as an antibiotic: The effect of inspired oxygen on infection. *Arch Surg* 1984; 119: 199-204.
52. Rabkin J, Hunt TK. Infection and oxygen. In: *Problem Wounds: The role of oxygen*. Davis JC, Hunt TK eds. Elsevier, New York 1988, p.1-16.
53. Jonsson K, Hunt TK, Mathes SJ. Oxygen as an isolated variable influences resistance to infection. *Ann Surg* 1988; 208(6): 783-787.

DIABETIC FOOT WOUND  
BIBLIOGRAPHY  
Provided to Medicare/Medicaid  
for Coverage of HBOT Treatment of Diabetic Foot Wounds  
by Paul G. Harch MD

54. Knighton DR, Halliday B, Hunt TK. Oxygen as an antibiotic: A comparison of inspired oxygen concentration and antibiotic administration on in vivo bacterial clearance. *Arch Surg* 1986; 121: 191-195.
55. Mandell G. Bactericidal activity of aerobic and anaerobic polymorphonuclear neutrophils. *Infect Immun* 1974; 9: 337-341.
56. Mader JT, Brown GL, Guckian JC, et al. A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. *J Infect Dis* 1980; 142: 915-922.
57. Mader JT, Adams KR, Sulton TE. Infectious diseases: pathophysiology and mechanisms of hyperbaric oxygen. *J Hyperbaric Med* 1987; 2: 133-140.
58. Thom SR, Lauermaun MW, Hart GB. Intermittent hyperbaric oxygen therapy for reduction of mortality in experimental polymicrobial sepsis. *J Infect Dis* 1986; 154: 504-510.
59. Thom SR. Hyperbaric oxygen therapy in septicemia. *J Hyperbaric Med* 1987; 2: 141-146.
60. Robson MC, Stenberg BD, Hegggers JP. Wound healing alterations caused by infection. *Clin Plast Surg* 1990; 17(3): 485-492.
61. Hunt TK. The physiology of wound healing. *Ann Emerg Med* 1988; 17: 1265-1273.
62. Millington JT, Norris TW. Effective treatment strategies for diabetic foot wounds. *J Fam Pract* 2000; 49(11): S40-48.
63. Stotts NA, Wipke-Tevis D. Co-factors in impaired healing. In: *Chronic Wound Care: A clinical source book for healthcare professionals, 2<sup>nd</sup> ed.* Krasner D, Kane D, eds. Wayne, Pa: Health Management Publications, Inc 1997, p.64-72.
64. Wells CH, Goodpasture JE, Horrigan DJ, Hart GB. Tissue gas measurements during hyperbaric oxygen exposure. In: *Proceedings of the 6<sup>th</sup> International Conference on Hyperbaric Medicine.* Smith G, ed. Aberdeen University Press 1977, p.118-124.
65. Niinikoski J, Aho AJ. Combination of hyperbaric oxygen, surgery, and antibiotics in the treatment of clostridial gas gangrene. *Infect Surg* 1983; 2: 23-37.
66. Siddiqui A, Davidson JD, Mustoe TA. Ischemic tissue oxygen capacitance after hyperbaric oxygen therapy: A new physiologic concept. *Plast Reconstr Surg* 1997; 99: 148-155.
67. Brummelkamp WH. Considerations on hyperbaric oxygen therapy at three atmospheres absolute for clostridial infections type welchii. *Ann NY Acad Sci* 1965; 117: 688-699.
68. McCord JM, Keele B, Fridovich I. An enzyme based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. *Proc Natl Acad Sci USA* 1971; 68: 1024-1027.
69. McAllister TA, Stark JM, Norman JN, Ross RM. Inhibitory effects of hyperbaric oxygen on bacteria and fungi. *Lancet* 1963; 2: 1040-1042.
70. VanUnnik AJM. Inhibition of toxin production in *Clostridium perfringens in vitro* by hyperbaric oxygen. *Antonie Van Leeuwenhoek* 1965;31: 181-186.
71. Verklin RM, et al. Alteration of effectiveness of antibiotics by anaerobiosis. *J Lab Clin Med* 1977; 89(1): 65-71.
72. Harrell LJ, et al. Effect of anaerobiosis on antimicrobial susceptibility of staphylococci. *Antimicrob Agents Chemother* 1977; 11: 1077-1078.
73. Keck PE, Gottlieb SF, Conley J. Interaction of increased pressures of oxygen and sulfonamides on the *in vitro* and *in vivo* growth of pathogenic bacteria. *Undersea Biomed Res* 1980; 7: 95-106.
74. Norden CW. Experimental osteomyelitis V. Therapeutic trials with oxacillin and sisomicin alone and in combination. *J Infect Dis* 1978; 137: 155-160.
75. Tack KJ, et al. Increased minimum inhibitory concentrations with anaerobiosis for tobramycin, gentamicin, and amikacin, compared to latamoxef, piperacillin, chloramphenicol, and clindamycin. *Chemotherapy* 1985; 33: 204-210.
76. Adams KR, Mader JT. Aminoglycoside potentiation with adjunctive hyperbaric oxygen therapy in *experimental Pseudomonas aeruginosa* osteomyelitis. *Undersea Biomedical Research* 1987; 14(2), Suppl: 37-8.
77. Adams KR, Sutton TE, Mader JT. *In vitro* potentiation of tobramycin under hyperoxic conditions. *Undersea Biomedical Research* 1987; 14(2), Suppl: 37.
78. Hehenberger K, Brismar K, Lind F, Kratz G. Dose-dependent hyperbaric oxygen stimulation of human fibroblast proliferation. *Wound Rep Regen* 1997; 5: 147-50.

DIABETIC FOOT WOUND  
BIBLIOGRAPHY  
Provided to Medicare/Medicaid  
for Coverage of HBOT Treatment of Diabetic Foot Wounds  
by Paul G. Harch MD

79. Winter GD, Perrins DJD. Effects of hyperbaric oxygen treatment on epidermal regeneration. In: Proceedings of the Fourth International Congress on Hyperbaric Medicine. Wada J, Iwa T, eds. The Williams and Wilkins Co., Baltimore, MD, 1970, p.363-368.
80. Ketchum SA III, Thomas AN, Hall AD. Angiographic studies of the effects of hyperbaric oxygen on burn wound revascularization. In: Proceedings of the Fourth International Congress on Hyperbaric Medicine. Wada J, Iwa T, eds. The Williams and Wilkins Co., Baltimore, MD, 1970, p.388-394.
81. Tompach PC, Lew D, Stoll JL. Cell response to hyperbaric oxygen treatment. *Int J Oral Maxillofac Surg* 1997; 26: 82-86.
82. Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. *JADA* 1985; 111: 49-55.
83. Zhao LL, Davidson JD, Wee SC, Roth SI, Mustoe TA. Effect of hyperbaric oxygen and growth factors on rabbit ear ischemic ulcers. *Arch Surg* 1994; 129: 1043-1049.
84. Wu L, Mustoe TA. Effect of ischemia on growth factor enhancement of incisional wound healing. *Surgery* 1995; 117: 570.
85. Reenstra WR, Dittmer C, Buras JA. Human dermal fibroblasts vary the expression of growth factor receptors in response to in vitro oxygen levels. *Undersea Hyper Med* 1999; 26 (Suppl): 71.
86. Bonomo SR, Davidson JD, Yu Y, et al. Hyperbaric oxygen as a signal transducer: upregulation of platelet derived growth factor-beta receptor in the presence of HBO, and PDGF. *Undersea Hyper Med* 1998; 25(4): 211-216.
87. Sheikh AY, Gibson JJ, Rollins MD, et al. Effect of hyperoxia on vascular endothelial growth factor levels in a wound model. *Arch Surg* 2000; 135: 1293-1297.
88. Garret IR, et al. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. *J Clin Invest* 1990; 85(3): 632-639.
89. Barth E, Sullivan T, Berg E. An animal model for evaluating bone repair with and without adjunctive hyperbaric oxygen therapy (HBO): Comparing dose schedules. *J Invest Surg* 1990; 3: 387-392.
90. Ueng SW, et al. Bone healing of tibial lengthening is enhanced by hyperbaric oxygen therapy: a study of bone mineral density and torsional strength on rabbits. *J Trauma* 1998; 44(4): 676-681.
91. Buras JA, Stahl GL, Svoboda KKH, Reenstra WR. Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. *Am J Physiol Cell Physiol* 2000; 278: C292-302.
92. Schaffer MR, Tantry U, Gross SS, Wasserburg HL, Barbul A. Nitric oxide regulates wound healing. *J Surg Res* 1996; 63(1): 237-40.
93. Bruch-Gerharz D, Ruzicka T, Kolb-Bachofen V. Nitric oxide in human skin: current status and future prospects. *J Invest Dermatol* 1998; 110: 1-7.
94. Beckman JS. The physiological and pathological chemistry of nitric oxide. In: *Nitric Oxide*. Lancaster J, ed. Academic Press, New York, NY, 1996, p.1-71.
95. Noiri E, Lee D, Testa J, et al. Podokinesis in endothelial cell migration: role of nitric oxide. *Am J Physiol* 1998; 274(1 Pt 1): C236-C244.
96. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. *Cardiovasc Res* 1996; 32: 743-51.
97. Shen YH, Wang XL, Wilcken DE. Nitric oxide induces and inhibits apoptosis through different pathways. *FEBS Lett* 1998; 433(1-2): 125-31.
98. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. *J Clin Invest* 1997; 100: 3131-9.
99. Davis JC. The use of adjuvant hyperbaric oxygen in the treatment of the diabetic foot. *Clin Pod Med Surg*, 1987;4(2): 429-437.
100. Cianci P, Petrone G, Drager S, et al. Salvage of the problem wound and potential amputation with wound care and adjunctive hyperbaric oxygen therapy: An economic analysis. *J Hyper Med* 1988; 3: 127-141.
101. Wattel FE, Mathieu DM, et al. Hyperbaric oxygen in the treatment of diabetic foot lesions: Search for healing predictive factors. *J Hyperbaric Med*, 1991; 6(4): 263-267.
102. Oriani G. Diabetic foot and hyperbaric oxygen therapy: A ten year experience. *J Hyperbaric Med*, 1992; 7(4): 213-221.
103. Cianci P, Hunt TK. Long term results of aggressive management of diabetic foot ulcers suggest significant cost effectiveness. *Wound Repair and Regen* 1997; 5: 141-146.

DIABETIC FOOT WOUND  
BIBLIOGRAPHY  
Provided to Medicare/Medicaid  
for Coverage of HBOT Treatment of Diabetic Foot Wounds  
by Paul G. Harch MD

104. Stone JA, Scott RG, Brill LR, Levine BD. The role of hyperbaric oxygen therapy in the treatment of the diabetic foot. *Diabetes*, 1995; 44(Suppl 1): 71A.
105. Oriani G, Meazza D, Favales F, et al. Hyperbaric oxygen therapy in diabetic gangrene. *J Hyperbaric Med* 1990; 5: 171-175.
106. Baroni G, Porro T, Faglia E, et al. Hyperbaric oxygen in diabetic gangrene treatment. *Diabetes Care* 1987; 10: 81-86.
107. Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. *J Postgrad Med* 1992; 38(3): 112-4.
108. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. *Diabetes Care* 1996; 19: 1338-1343.
109. Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA. Evaluation of hyperbaric oxygen for diabetic wounds: A prospective study. *Undersea Hyperbaric Med* 1997; 24: 175-179.
110. Abidia A, Kuhan G, Laden G, et al. Hyperbaric oxygen therapy for diabetic leg ulcers-a double-blind randomised-controlled trial. *Undersea Hyper Med* 2001; 28(Suppl): 64.
111. Lin TF, Chen SB, Niu KC. The vascular effects of hyperbaric oxygen therapy in treatment of early diabetic foot. *Undersea Hyper Med* 2001; 28(Suppl): 67.
112. Cianci P. Review: Adjunctive hyperbaric oxygen therapy in the treatment of the diabetic foot. *Wounds* 1992; 4(5): 158-166.
113. Mackey WC, McCullough JL, Conlon TP, et al. The cost of surgery for limb-threatening ischemia. *Surgery* 1986; 99: 26-35.
114. Ebskov G, Josephesen P. Incidence of reamputation and death after gangrene of the lower extremity. *Prosthet Orthotics Inter* 1980; 4: 77-80.
115. Couch NP, David JK, Tilney NL, Crane C. Natural history of the leg amputee. *Am J Surg* 1977; 133: 469-473.
116. Gibbons GW, Marcaccio EJ Jr, Burgess AM, et al. Improved quality of diabetic foot care, 1984 vs. 1990. *Arch Surg* 1993; 128: 576-81.
117. Cianci P. Adjunctive hyperbaric oxygen therapy in the treatment of the diabetic foot. *J Am Pod Med Assoc* 1994; 84: 448-55.
118. Boulton AJM, Vileikyte L. The diabetic foot: the scope of the problem. *J of Fam Pract*, 2000; 49(11): S3-S8.
119. Williams DRR, Airey CM. The size of the problem: epidemiological and economic aspects of foot problems in diabetes. In: *The foot in diabetes, 3<sup>rd</sup> ed.* Boulton AJM, Connor H, Cavanagh PR, eds. Chichester, England. John Wiley and Sons, 2000. p.3-16.
120. Brod M. Quality of life issues in patients with diabetes and lower-extremity ulcers: patients and care givers. *Qual Life Res* 1998; 7: 365-72.
121. Abidia A, Kuhan G, Laden G, et al. The placebo effect of hyperbaric oxygen therapy-fact or fiction? *Undersea Hyper Med* 2001; 28(Suppl): 57-8.
122. The Blue Cross and Blue Shield Association, Technical Assessment Center; Assessment Program, August 1999; 14(13).
123. Hyperbaric Oxygen Therapy, April 2000. Medicare Service Advisory Committee application 1018-1020. Draft final assessment report. Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601.
124. Hunt D, and Gerstein H. Foot ulcers in diabetes. *Clinical Evidence* 2001; 5: 397-402.
125. American Diabetes Association. "Consensus Development Conference on Diabetic Foot Wound Care, 7-8 April, 1999, Boston, MA." *Diabetes Care*, 1999; 22: 1354-1360.
126. Ollendorf DA, Kotsanos JG, Wishner WJ, et al.. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. *Diabetes Care* 1998; 21(8): 1240-5.
127. Rith-Najarian SJ, Reiber GE. Prevention of foot problems in persons with diabetes. *J Fam Pract* 2000; 49(suppl): S30-S39.
128. Lavery L, Gazewood JD. Assessing the feet of patients with diabetes. *J Fam Pract* 2000; 49(suppl): S9-S16
129. Department of Health and Human Services. Healthy people 2000: national health promotion and disease prevention objectives. Washington, DC: Government Printing Office; 1991: 73-117.